Cite
HARVARD Citation
Davis, A. et al. (2023). A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated Tuberculous Meningitis: The LASER-TBM Trial. Clinical infectious diseases. pp. 1412-1422. [Online].